S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:TERN

Terns Pharmaceuticals - TERN Stock Forecast, Price & News

$8.94
-0.13 (-1.43%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.73
$9.23
50-Day Range
$5.53
$10.18
52-Week Range
$1.45
$10.67
Volume
308,591 shs
Average Volume
141,640 shs
Market Capitalization
$336.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Terns Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
0.7% Upside
$9.00 Price Target
Short Interest
Healthy
3.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
1.43mentions of Terns Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$8.25 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.91) to ($1.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

484th out of 1,053 stocks

Pharmaceutical Preparations Industry

245th out of 519 stocks


TERN stock logo

About Terns Pharmaceuticals (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Receive TERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TERN Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Terns Announces Proposed Public Offering
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
TELL, ICPT and VKTX among mid-day movers
New Analysts Initiate Coverage: 3 Top-Ranked Stocks to Buy
New Analysts Initiate Coverage: 3 Top-Ranked Stocks to Buy
See More Headlines
Receive TERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TERN Company Calendar

Last Earnings
11/09/2022
Today
2/02/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TERN
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+0.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-50,160,000.00
Pretax Margin
-5,829.60%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$6.34 per share

Miscellaneous

Free Float
29,715,000
Market Cap
$336.23 million
Optionable
Not Optionable
Beta
-1.01

Key Executives

  • Mr. Senthil Vel Sundaram (Age 44)
    CEO & Director
    Comp: $850.2k
  • Dr. Erin Quirk M.D. (Age 51)
    Pres & Head of R&D
    Comp: $662.55k
  • Mr. Seokho Yoon Esq. (Age 44)
    COO, Gen. Counsel & Sec.
    Comp: $609.37k
  • Dr. Weidong Zhong Ph.D. (Age 56)
    Co-Founder & Exec. Officer
  • Dr. Mark Joseph Vignola (Age 44)
    CFO & Treasurer
  • Dr. Jeffrey R. Jasper Ph.D.
    Sr. VP & Head of Research
  • Ms. Diana Chung
    Sr. VP & Chief Devel. Officer
  • Dr. Kerry Russell M.D.
    Ph.D., Chief Medical Officer













TERN Stock - Frequently Asked Questions

Should I buy or sell Terns Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TERN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TERN, but not buy additional shares or sell existing shares.
View TERN analyst ratings
or view top-rated stocks.

What is Terns Pharmaceuticals' stock price forecast for 2023?

3 equities research analysts have issued 1-year target prices for Terns Pharmaceuticals' stock. Their TERN share price forecasts range from $6.00 to $14.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 0.7% from the stock's current price.
View analysts price targets for TERN
or view top-rated stocks among Wall Street analysts.

How have TERN shares performed in 2023?

Terns Pharmaceuticals' stock was trading at $10.18 at the beginning of 2023. Since then, TERN shares have decreased by 12.2% and is now trading at $8.94.
View the best growth stocks for 2023 here
.

When is Terns Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our TERN earnings forecast
.

How were Terns Pharmaceuticals' earnings last quarter?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) posted its quarterly earnings results on Wednesday, November, 9th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.07.

When did Terns Pharmaceuticals IPO?

(TERN) raised $101 million in an initial public offering on Friday, February 5th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

What is Terns Pharmaceuticals' stock symbol?

Terns Pharmaceuticals trades on the NASDAQ under the ticker symbol "TERN."

Who are Terns Pharmaceuticals' major shareholders?

Terns Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.52%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Insiders that own company stock include Biosciences Fund V LP Lav, Hongbo Lu, James E Flynn, Orbimed Advisors Llc, Vivo Capital Fund Viii, LP and Vivo Opportunity, Llc.
View institutional ownership trends
.

How do I buy shares of Terns Pharmaceuticals?

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Terns Pharmaceuticals' stock price today?

One share of TERN stock can currently be purchased for approximately $8.94.

How much money does Terns Pharmaceuticals make?

Terns Pharmaceuticals (NASDAQ:TERN) has a market capitalization of $336.23 million and generates $1 million in revenue each year. The company earns $-50,160,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

How can I contact Terns Pharmaceuticals?

Terns Pharmaceuticals' mailing address is 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404. The official website for the company is www.ternspharma.com. The company can be reached via phone at 650-525-5535 or via email at investors@ternspharma.com.

This page (NASDAQ:TERN) was last updated on 2/2/2023 by MarketBeat.com Staff